A new type of liquid silymarin proliposome containing bile salts: Its preparation and improved hepatoprotective effects

PLoS ONE

Volumn 10, Issue 12, 2015, Pages

  Wang, Mei ^a   Xie, Tingting ^b   Chang, Zhanying ^a   Wang, Ling ^a   Xie, Xiangyun ^a   Kou, Yaohong ^a   Xu, Hongxia ^a   Gao, Xiaoli ^a  

^a XINJIANG MEDICAL UNIVERSITY   (China)

^b CHINESE PLA GENERAL HOSPITAL   (China)

Author keywords

[No Author keywords available]

Indexed keywords

3,4 METHYLENEDIOXYAMPHETAMINE; AMINOTRANSFERASE; BACTERIUM LIPOPOLYSACCHARIDE; BILE SALT; CARBON TETRACHLORIDE; DRUG CARRIER; GALACTOSAMINE; GLUTATHIONE PEROXIDASE; PROLIPOSOME; SILYMARIN; SUPEROXIDE DISMUTASE; UNCLASSIFIED DRUG; BILE ACID; BIOLOGICAL MARKER; LIPOSOME; PROTECTIVE AGENT; REACTIVE OXYGEN METABOLITE;

ACUTE HEPATITIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG ABSORPTION; DRUG DOSAGE FORM; DRUG DOSAGE FORM COMPARISON; DRUG DOSE COMPARISON; DRUG EFFECT; DRUG FORMULATION; DRUG SCREENING; DRUG SOLUBILITY; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TRANSPORT; ENCAPSULATION; ENZYME BLOOD LEVEL; HISTOPATHOLOGY; IN VITRO STUDY; IN VIVO STUDY; INTESTINE ABSORPTION; LIPOSOMAL DELIVERY; LIVER PROTECTION; NONHUMAN; PARTICLE SIZE; RAT; ZETA POTENTIAL; ANIMAL; ANIMAL HEPATITIS; BIOPSY; CHEMISTRY; DISEASE MODEL; DRUG EFFECTS; HEPATITIS; LIVER; LIVER FUNCTION TEST; METABOLISM; MOUSE; OXIDATION REDUCTION REACTION; PATHOLOGY; PH;

ANIMALS; BILE ACIDS AND SALTS; BIOMARKERS; BIOPSY; DISEASE MODELS, ANIMAL; HEPATITIS; HEPATITIS, ANIMAL; HYDROGEN-ION CONCENTRATION; INTESTINAL ABSORPTION; LIPOSOMES; LIVER; LIVER FUNCTION TESTS; MICE; OXIDATION-REDUCTION; PARTICLE SIZE; PROTECTIVE AGENTS; RATS; REACTIVE OXYGEN SPECIES; SILYMARIN;

EID: 84956942010     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0143625     Document Type: Article

References (31)

1. Ghosh A, Ghosh T, Jain S. Silymarin.-A review of the pharmacodynamics and bioavailability enhancement approaches. J Pharm Sci and Tech 2012; 2:348-55.
2. Theodosiou E, Purchartová K, Stamatis H, Kolisis F, Křen V. Bioavailability of silymarin flavonolignans: drug formulations and biotransformation. Phytochem Rev 2014; 13:1-18.
3. Li X, Yuan Q, Huang Y, Zhou Y, Liu Y. Development of silymarin self-microemulsifying drug delivery system with enhanced oral bioavailability. AAPS Pharm Sci Tech 2010; 11:672-78.
4. Sonali D, Tejal S, Vaishali T, Tejal G. Silymarin-solid dispersions: characterization and influence of preparation methods on dissolution. Acta Pharm 2010; 60:427-43. doi: 10.2478/v10007-010-0038-3 PMID: 21169135
5. Barzaghi N, Crema F, Gatti G, Pifferi G, Perucca E. Pharmacokinetic studies on IdB1016, a silybinphosphatidylcholine complex, in healthy human subjects. Eur J Drug Metab Pharmacokinet 1990; 15:338-8.
6. Zhang Y, Li J. Preparation and in vitro release of silymarin-loaded polyethylene glycol modified liposomes, pharmaceutical and clinical. Resources 2010; 18:239-42.
7. Elmowafy M, Viitala T, Ibrahim HM, Abu-Elyazid SK, Samy A, Kassem A. et al. Silymarin loaded liposomes for hepatic targeting: in vitro evaluation and HepG2 drug uptake. Eur J Pharm Sci 2013; 50:161-71. doi: 10.1016/j.ejps.2013.06.012 PMID: 23851081
8. Wu W, Wang Y, Que L. Enhanced bioavailability of silymarin by self-microemulsifying drug delivery system. Eur J Pharm Biopharm 2006; 63:288-94. PMID: 16527467
9. Liu LJ, Pang XJ, Zhang W, Wang S. Formulation design and in vitro evaluation of silymarin-loaded selfmicroemulsifying drug delivery systems. Asian J Pharm 2007; 2:150-60.
10. Parveen R, Baboota S, Ali J, Ahuja A, Vasudev SS, Ahmad S. Oil based nanocarrier for improved oral delivery of silymarin: in vitro and in vivo studies. Int J Pharm 2011; 413:245-53. doi: 10.1016/j.ijpharm. 2011.04.041 PMID: 21549187
11. Cao X, Fu M, Wang L, Liu H, Deng W, Qu R. et al. Oral bioavailability of silymarin formulated as a novel 3-day delivery system based on porous silica nanoparticles. Acta Biomater 2012; 8:2104-12. doi: 10. 1016/j.actbio.2012.02.011 PMID: 22343518
12. Maherani B, Arab-Tehrany E, R. Mozafari M, Gaiani C, Linder M. Liposomes: a review of manufacturing techniques and targeting strategies. Curr Nanosci 2011; 7:436-52.
13. Karn PR, Cho W, Hwang SJ. Liposomal drug products and recent advances in the synthesis of supercritical fluid-mediated liposomes. Nanomedicine (Lond) Nanomedicine (Lond) 2013; 8:1529-48.
14. Kumar N, Rai A, Reddy ND, Raj PV, Jain P, Deshpande P. et al. Silymarin liposomes improves oral bioavailability of silybin besides targeting hepatocytes, and immune cells. Pharmacol Rep 2014; 66:788-98. doi: 10.1016/j.pharep.2014.04.007 PMID: 25149982
15. Shaji J, Proliposomes BV. A brief overview of novel delivery system. Int J Pharm Bio Sci 2013; 4:150-60.
16. Wang J, Li MX. The development of the proliposome. J Chin Med Industry 2005; 36:707-11.
17. Potluri P, Betageri GV. Mixed-micellar Proliposomal systems for enhanced oral Delivery of progesterone. Drug Deliv 2006; 13:227-32. PMID: 16556576
18. Wagner A, Vorauer-Uhl K. Liposome Technology for Industrial purposes [Online] 2011. Available at: http://www.hindawi.com/journals/jdd/2011/591325/. Accessed on 20 October 2010.
19. Sun C, Wang J, Liu J, Qiu L, Zhang W, Zhang L. Liquid Proliposomes of Nimodipine Drug Delivery system: preparation, characterization, and pharmacokinetics. AAPS PharmsciTech 2013; 14:332-8. doi: 10.1208/s12249-013-9924-6 PMID: 23319300
20. Hildebrand A, Beyer K, Neubert R, Garidel P, Blume A. Temperature dependence of the interaction of cholate and deoxycholate with fluid model membranes and their solubilization into mixed micelles. Colloids Surf B Biointerfaces 2003; 32:335-51.
21. Kossena GA, Boyd BJ, Porter CJ, Charman WN. Separation and characterization of the colloidal phases produced on digestion of common formulation lipids and assessment of their impact on the apparent solubility of selected poorly water-soluble drugs. J Pharm Sci 2003; 92:634-48. PMID: 12587125
22. Porter CJ, Trevaskis NL, Charman WN. Lipids and lipid-based formulations: optimizing the oral delivery of lipophilic drugs. Nat Rev Drug Discov 2007; 6:231-48. PMID: 17330072
23. Gao XL, Kzybek M, Wen H. [In vivo distribution of a novel proliposomal preparation of tegafur following intragastric gavage to rats]. Yao Xue Xue Bao 2005; 40:1139-43. PMID: 16496681
24. Wang M, Gao XL. Determination of the entrapment efficiency of progesterone proliposome. Chin J New Drugs 2011; 20:75-7.
25. Chu C, Tong SS, Xu Y, Wang L, Fu M, Ge YR. et al. Proliposomes for oral delivery of dehydrosilymarin: preparation and evaluation in vitro and in vivo. Acta Pharmacol Sin 2011; 32:973-80. doi: 10.1038/aps. 2011.25 PMID: 21666703
26. Niu M, Lu Y, Hovgaard L,WuW. Liposomes containing glycocholate as potential oral insulin delivery systems:preparation, in vitro evaluation and improved protective effect of cholate type, particle size and administered dose. Eur J Pharm, Biopharm 2011; 81:265-72.
27. Hiremath PS, Soppimath KS, Betageri GV. Proliposomes of exemestane for improved oral delivery: formulation and in vitro evaluation using PAMPA, Caco-2 and rat intestine. Int J Pharm 2009; 380:96-104. doi: 10.1016/j.ijpharm.2009.07.008 PMID: 19616608
28. Alam MA, Al-Jenoobi FI, Al-mohizea AM. Everted gut sac model as a tool in pharmaceutical research: limitations and applications. J Pharm Pharmacol 2012; 64:326-36. doi: 10.1111/j.2042-7158.2011. 01391.x PMID: 22309264
29. El-Samaligy MS, Afifi NN, Mahmoud EA. Evaluation of hybrid liposomes-encapsulated silymarin regarding physical stability and in vivo performance. Int J Pharm 2006; 319:121-29. PMID: 16837151
30. Chen Y, Lu Y, Chen J, Lai J, Sun J, Hu F. et al. Enhanced bioavailability of the poorly water-soluble drug fenofibrate by using liposomes containing a bile salt. Int J Pharm 2009; 376:153-60. doi: 10.1016/j.ijpharm.2009.04.022 PMID: 19394416
31. Rao S, Tan A, Thomas N, Prestidge CA. Perspective and potential of oral lipid-based delivery to optimize pharmacological therapies against cardiovascular diseases. J Control Release 2014; 193:174-87. doi: 10.1016/j.jconrel.2014.05.013 PMID: 24852093